Table 1.
Genitourinary-oncologic Xenograft Study Treatment Schedules.
| Study | n | Treatment | Dose | Route | Schedule | NanoDoce® Designation |
|---|---|---|---|---|---|---|
| Renal Cancer Xenograft (786-O in rat) |
3 | Untreated | N/A | N/A | N/A | - |
| 3 | Vehicle | - | IT | qweekly 3× | - | |
| 3 | Docetaxel | 2.5–5 mg/kg | IV | qweekly 2–3× | - | |
| 3 | NanoDoce® | 20 mg/kg | IT | qweekly 1× | 1× | |
| 3 | 20 mg/kg | IT | qweekly 2× | 2× | ||
| 3 | 20 mg/kg | IT | qweekly 3× | 3× | ||
| Bladder Cancer Xenograft (UM-UC-3 in mouse) |
1 | Untreated | N/A | N/A | N/A | - |
| 10 | Vehicle | - | IT | qweekly 3× | - | |
| 9 | Docetaxel | 30 mg/kg | IV | qweekly 3× | - | |
| 10 | NanoDoce® | 100 mg/kg | IT | qweekly 1× | 1× | |
| 9 | 100 mg/kg | IT | qweekly 2× | 2× | ||
| 9 | 100 mg/kg | IT | qweekly 3× | 3× | ||
| Prostate Cancer Xenograft (PC-3 in mouse) |
10 | Vehicle | - | IT | qweekly 3× | - |
| 10 | Docetaxel | 30 mg/kg | IV | qweekly 3× | - | |
| 10 | NanoDoce® | 100 mg/kg | IT | qweekly 1× | Low | |
| 10 | 37.5 mg/kg | IT | qweekly 3× | Medium | ||
| 10 | 100 mg/kg | IT | qweekly 3× | High |